Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Dermatomycoses Market Growth in 2025?

The market for dermatomycoses has seen robust growth recently. It is forecasted to expand from a size of $14.12 billion in 2024 to $14.95 billion in 2025, signifying a compound annual growth rate (CAGR) of 5.9%. The growth witnessed in the historical period is linked to advancements in antifungal treatments, a rising incidence of fungal infections, growing consciousness about skin health, improved diagnostic methods, and widened availability of over-the-counter antifungal products.

What Is the Forecast for the Dermatomycoses Market Size Through 2029?

The market size for dermatomycoses is set to experience significant growth in the upcoming years, escalating to $18.59 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 5.6%. This predicted growth is due to factors such as a rising aging population, an increase in drug-resistant fungal strains, an escalated demand for natural and organic antifungal products, advancements in the field of biotechnology and antifungal research, and greater accessibility to healthcare in developing regions. The forecast period will likely witness key trends such as the creation of new antifungal medications, progress in quick diagnostic methods, the application of artificial intelligence in dermatology, advancements in nanotechnology for antifungal treatments, and breakthroughs in microbiome-based therapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21934&type=smp

What are the Key Market Players in Dermatomycoses Market and How They’re Evolving?

Major companies operating in the dermatomycoses market are Pfizer Inc., Bayer AG, Saphnix Life Sciences, MITS Healthcare Private Limited, Weefsel Pharma, AdvaCare Pharma, Associated Biotech, Healthy Life Pharma Private Limited, Blueberry Therapeutics Ltd., Livealth Biopharma Pvt. Ltd., LGM Pharma, SiNi Pharma Pvt. Ltd., Joshi Agrochem Pharma Private Limited, Wellona Pharma, Abiba Pharmacia Pvt. Ltd., Vee Excel Drugs & Pharmaceuticals Pvt. Ltd., Femcorp Pharma, Lexicare Pharma Pvt. Ltd., Glamris Dermacare, Henin Lukinz

What Are the Primary Growth Drivers in the Dermatomycoses Market?

The surge in the number of fungal infections is anticipated to stimulate the expansion of the dermatomycoses market. These infections are caused by fungi that compromise the skin, nails, hair, or internal organs, leading to a variety of health complications. The use of wide-ranging antibiotics in excess can disrupt the natural microbiome, allowing fungi to proliferate and cause infections. This microbial imbalance diminishes the body’s innate defense mechanisms, making people more susceptible to opportunistic fungal infections. Dermatomycoses, produced by dermatophytes, yeasts, and molds, account for fungal diseases, influencing various tissues and leading to widespread superficial and systemic infections. For instance, as per the UK Health Security Agency’s report in November 2023, global incidence estimates point to 6.5 million invasive fungal infections annually, leading to roughly 3.8 million fatalities, with 2.5 million directly related to these infections. Hence, the rise in fungal infection occurrences is stimulating the growth of the dermatomycoses market. The growing preference for oral drugs, due to their convenience and effectiveness, is expected to propel the dermatomycoses market’s expansion. Oral medications, which come in the form of tablets, capsules, or liquids and are digested through the gastrointestinal system, are experiencing a surge in demand. These drugs are more favored than injections or other delivery modes because they are convenient and capable of treating a wide array of conditions effectively. Dermatomycoses accentuate the use of oral medicines, allowing systemic antifungal agents to reach the infected skin, hair, or nails via the bloodstream—ensuring a deeper and more extended treatment compared to topical applications. In October 2022, the Centers for Disease Control and Prevention, an agency of the US government, reported that the dispensing of oral antivirals had increased by 57%, up from 643 per 100,000 individuals between April 24 and May 21, 2022, to 1,012 per 100,000 individuals between July 31 and August 28, 2022. Thus, the growing demand for oral medications is accelerating the growth of the dermatomycoses market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21934&type=smp

What Are the Leading Segments in the Global Dermatomycoses Industry?

The dermatomycoses market covered in this report is segmented –

1) By Drugs: Corticosteroids, Corticosteroid-Sparing Agents, Immunosuppressive, Immunomodulator, Antifungals, Other Drugs

2) By Route Of Administration: Oral, Parenteral, Topical, Other Routes Of Administration

3) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegmentss:

1) By Corticosteroids: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids

2) By Corticosteroid-Sparing Agents: Tacrolimus, Pimecrolimus

3) By Immunosuppressive: Methotrexate, Azathioprine, Cyclophosphamide

4) By Immunomodulator: Interferon-Gamma, Thalidomide

5) By Antifungals: Topical Antifungals, Oral Antifungals, Systemic Antifungals

6) By Other Drugs: Antihistamines, Antibacterial Agents

What Are the Key Market Trends in the Dermatomycoses Industry?

Key enterprises in the dermatomycoses market are concentrating on exploring new potential drugs to enhance the treatment of onychomycosis and its results. Investigational new drug (IND) candidates, pharmaceutical compounds that undergo preclinical or clinical trials to assess their safety, effectiveness, and potential for being approved as treatments, are being specifically focused on. For example, in January 2024, the US Food and Drug Administration (FDA) approved a US-based biopharmaceutical firm, Vanda Pharmaceuticals Inc.’s Investigational New Drug candidate VTR-297 for onychomycosis treatment. The distinguishing aspect of VTR-297 is its histone deacetylase (HDAC) inhibitor properties, which sets it apart from conventional antifungal treatments. It targets the core issue of fungal proliferation, showing strong antifungal effects against dermatophytes and other fungi. This unique mode of action has the potential to provide quicker and more potent treatment outcomes while minimizing the risk of re-infection, thus addressing a major gap in the treatment of onychomycosis.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/dermatomycoses-global-market-report

What Is the Regional Outlook for the Dermatomycoses Market?

North America was the largest region in the dermatomycoses market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dermatomycoses market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21934

This Report Delivers Insight On:

1. How big is the dermatomycoses market, and how is it changing globally?

2. Who are the major companies in the dermatomycoses market, and how are they performing?

3. What are the key opportunities and risks in the dermatomycoses market right now?

4. Which products or customer segments are growing the most in the dermatomycoses market?

5. What factors are helping or slowing down the growth of the dermatomycoses market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model